Prof Andrew Roberts
Metcalf Chair in Leukaemia Research
Centre for Cancer Research
550 Scholarly works
5 Projects
HIGHLIGHTS
2025
Research grants (ARC, NHMRC, MRFF)
Enhancing the Activity of BH3 Mimetic Drugs in Blood Cancers
2023
Journal article
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
DOI: 10.1182/blood.20220160902022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752020
Research grants (ARC, NHMRC, MRFF)
Exploring the Potential of BH3 Mimetic Anti-Cancer Drugs in Blood Cancers
2017
Research Grant
The International Acute Myeloid Leukaemia Platform Consortium (Iapc)
RECENT SCHOLARLY WORKS
2026
Journal article
Abstract SY35-01: Enhancing BH3 mimetic drug induced killing of malignant cells for cancer therapy
DOI: 10.1158/1538-7445.am2026-sy35-012026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.20250166462026
Journal article
Blood: flowing stronger than ever after 80 years
DOI: 10.1182/blood.20250323752025
Journal article
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial
DOI: 10.1093/jac/dkaf3852025
Journal article
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia
DOI: 10.1002/hem3.702842025
Journal article
Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders
DOI: 10.1182/blood-2025-21302025
Journal article
3151 – PUTTING THE STING BACK INTO THERAPY FOR P53 MUTANT BLOOD CANCERS
DOI: 10.1016/j.exphem.2025.1050922025
Journal article
A case of enterovirus D68-associated acute flaccid myelitis in an immunocompromised adult, Australia.
DOI: 10.1128/asmcr.00074-25